耐甲氧西林金黄色葡萄球菌感染的新治疗选择。
New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus.
机构信息
Servicio de Microbiología Clínica y E. Infecciosas, Hospital General Universitario Gregorio Marañón, Universidad Complutenste, Madrid, and Ciber de Enfermedades Respiratories (CIBERES), Spain.
出版信息
Clin Microbiol Infect. 2009 Dec;15 Suppl 7:44-52. doi: 10.1111/j.1469-0691.2009.03091.x.
In recent years, a marked increase in the incidence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has occurred in many countries. This review addresses the effectiveness and limitations of drugs classically used for the treatment of MRSA, e.g. vancomycin, and also newer anti-MRSA antimicrobials, e.g. second-generation glycolipopeptides, tigecycline, and beta-lactams.
近年来，许多国家耐甲氧西林金黄色葡萄球菌（MRSA）感染的发病率显著增加。本综述讨论了经典用于治疗 MRSA 的药物（如万古霉素）以及新型抗 MRSA 抗菌药物（如第二代糖肽、替加环素和β-内酰胺类）的有效性和局限性。
Zotero 插件